MitoQ is commercially available as a dietary supplement and it has been tested as a potential drug in other diseases, but it has never been tested in patients with sickle cell disease. The goal of this research is to study if MitoQ, a molecule that works as an antioxidant by removing potentially damaging agents in a living organism, improves platelet function in patients with sickle cell disease (SCD).
Sickle Cell Disease
MitoQ is commercially available as a dietary supplement and it has been tested as a potential drug in other diseases, but it has never been tested in patients with sickle cell disease. The goal of this research is to study if MitoQ, a molecule that works as an antioxidant by removing potentially damaging agents in a living organism, improves platelet function in patients with sickle cell disease (SCD).
Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia
-
Magee Women's Hospital, Pittsburgh, Pennsylvania, United States, 15213
UPMC Montefiore, Pittsburgh, Pennsylvania, United States, 15213
UPMC Presbyterian, Pittsburgh, Pennsylvania, United States, 15213
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States, 15224
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States, 15232
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
Yes
University of Pittsburgh,
Ramasubramanian Kalpatthi, MD, PRINCIPAL_INVESTIGATOR, University of Pittsburgh
2026-06-30